Latest Medtech News
MedTech funding last week spanned at-home hormone testing, wearable blood pressure monitoring and non-invasive brain radiosurgery, alongside investment in AI surgical intelligence, microsurgical robots and advanced X-ray components. Beyond individual technologies, FFL Partners closed a $1.35B fund, 50% larger than its predecessor, signalling continued private equity appetite for healthcare and tech-enabled services.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like these. Subscribe to our Industry Insights for weekly coverage.
FFL Partners closes $1.35B fund to invest in healthcare and tech-enabled services
Private equity firm FFL Partners has closed its sixth fund with more than $1.35B in commitments, 50% larger than its predecessor fund, backed by existing and new institutional investors and family offices. Fund VI will target $50M-$200M equity investments in healthcare and tech-enabled services businesses, supporting growth through control or significant minority stakes.
Managing Partner Cas Schneller: "We are grateful for the enthusiastic support of our existing limited partners, and we are equally pleased to welcome a blue-chip group of new investors into Fund VI,"
ZAP Surgical raises $36M to expand non-invasive brain surgery
ZAP Surgical has secured $36M in financing led by Catalio Capital Management, with continued support from strategic partner Baheal. The funding will support global expansion and increased production of its ZAP-X robotic radiosurgery platform, which has been used to treat nearly 10,000 patients worldwide. The company is also exploring radiomodulation for conditions including treatment-resistant depression and addiction.
Founder and CEO John R. Adler: "As our understanding of the brain deepens, neuroscience will see unprecedented therapeutic breakthroughs over the coming decade. Scaling non-invasive, cost-effective therapy to tens of millions of patients worldwide will require strong, mission-aligned partners."
Beijing Zhishu raises RMB 200M to scale domestic CT X-ray tube production
Beijing Zhishu Technology has raised over RMB 200M ($29.9M) in Series C funding, co-led by CICC Capital and Zhejiang Provincial Investment, with participation from Shanxi Securities Innovation and existing investors. The funding will support automated manufacturing expansion, R&D and regulatory approvals for advanced CT and DSA X-ray tubes, and international market expansion as the company prepares for an IPO.
Founder Hu Yinfu
ABM Respiratory Care secures $20M to expand respiratory therapies
ABM Respiratory Care has secured a $20M growth capital commitment from Trinity Capital to accelerate global expansion and continued product development. The funding will support its BiWaze® platform for airway clearance, lung expansion and secretion management across hospital and home care settings, alongside clinical research and connected respiratory care technologies.
CEO Greg Miller: "This financing represents another significant milestone in ABM Respiratory Care's growth and financial evolution,"
DeepMed raises nearly RMB 100M to advance microsurgical robotics
Chinese medtech company DeepMed has completed a Series B round of nearly RMB 100M ($14.9M) , co-led by Mifang Health Fund and Shengshi Investment, with participation from additional investors and existing shareholder Wondfo Venture Capital. The funding will support clinical trials across multiple indications, regulatory approvals and domestic and international expansion of its FUNZAR microsurgical robot, designed for high-precision procedures under a microscope.
Founder Dr. Xia Jun
Inossia raises SEK 88M to advance bone cement technology
Swedish medtech company Inossia has raised SEK 88M ($8.8M), with the directed share issue primarily subscribed by Cradle Growth and the EIC Fund. The funding will support studies and preparations for U.S. market entry of its Cement Softener, designed to adjust bone cement stiffness to better match natural bone and reduce the risk of subsequent vertebral fractures. Half of the capital is conditional on FDA clearance.
CEO Malin Nilsson: "The fact that we are able to attract investors at this stage who both understand the product’s potential and are willing to invest is, in my view, a strong validation of the work we have accomplished so far,"
XRlabs raises €7.48M to advance AI-powered surgical intelligence
London-based XRlabs has raised €7.48M ($8.4M) in Seed funding, led by Playground Global with participation from Eka Ventures. The funding will support product development, team expansion and regulatory progress for its AI platform, which combines surgical video, imaging and navigation data to provide real-time intelligence in the operating room.
Founder Dr. Ali Haddad: "Our conviction is that the operating room is the next frontier for physical AI. Surgery generates extraordinary data, yet almost none of it becomes intelligence in the moments that matter most."
Cellbox Solutions closes €5M Series A to expand biological material logistics
German company Cellbox Solutions has completed its €5M ($5.59M) Series A, with participation from Baltic Business Angels Invest, existing investors NRW.BANK and Fraunhofer Venture. The funding will support international expansion and integrated logistics services for transporting sensitive biological materials under controlled temperature and CO₂ conditions.
Founder and CEO Prof. Dr. Kathrin Adlkofer: "With the successful completion of our Series A round, we are now expanding our established warm-chain technology platform into a broader offering for physiological logistics."
Unravel Health raises €2.96M to develop at-home hormone testing
Unravel Health has raised €2.96M ($3.3M), led by Conduit EIS Impact Fund and Wrightwood, with participation from Leo Capital, Embryo Ventures, Hermesa and Zinc VC. The funding will support validation studies, additional hormone markers and regulatory preparations for its palm-sized Micro Lab, designed to measure multiple hormones from saliva samples at home, with early-access devices targeted for 2027.
Co-Founder and CEO Veronika Bridgman: "Fifteen years ago I built my own hormone tracker to manage PCOS (now PMOS), because a blood test told me almost nothing about what my body was doing. Soon anyone will be able to bring the lab home to understand their symptoms,"
Yuhan invests 1B Won in Charmcare to expand wearable blood pressure monitoring
South Korean pharmaceutical company Yuhan Corporation has invested 1B Won ($754K) in medical device maker Charmcare, expanding its digital healthcare portfolio beyond drug development and ECG monitoring. The investment will support R&D, product supply and sales growth for Charmcare’s wearable blood pressure monitors, with potential collaboration in hospital monitoring, remote patient monitoring and home healthcare.
Founder and CEO Dong Hwa Lee
iCUREX raises JPY 140M to scale chitosan hydrogel wound dressing
Japanese medtech company iCUREX has raised140M Yen ($894K) through a 100M Yen ($638K) Series A first closing led by NCB Venture Capital, with participation from Greencore and INDEP, alongside a 40M Yen ($255K) loan from Japan Finance Corporation. The funding will expand production and support R&D of its Kitosura CX, a Class III-approved injectable chitosan hydrogel wound dressing launched in September 2026.
Founder and CEO Takayuki Takei: "However, for us, product launch is not the goal. Rather, we believe this is just the beginning. I will continue to listen attentively to the voices of those on the front lines of medical care and pursue research and development to bring new options to wound treatment."
Oasicare secures investment to commercialize childbirth device
Danish medtech company Oasicare has secured investment from UV (Unconventional Ventures) to commercialize ASISU, a CE-marked single-use device designed to reduce the risk of perineal tears during vaginal birth. The funding will support its Danish market rollout and further clinical evidence development, following testing involving more than 300 devices at Hvidovre Hospital.
Co-Founder and CEO Ditte Marie Fog Ibsen
